Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Ampulla of Vater Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(24)
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G12C
Ampulla of Vater Carcinoma
KRAS G12C
Ampulla of Vater Carcinoma
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
BRAF V600E
Ampulla of Vater Carcinoma
BRAF V600E
Ampulla of Vater Carcinoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Ampulla of Vater Carcinoma
No biomarker
Ampulla of Vater Carcinoma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
No biomarker
Ampulla of Vater Carcinoma
No biomarker
Ampulla of Vater Carcinoma
5-fluorouracil + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + leucovorin calcium
Sensitive
:
A2
5-fluorouracil + leucovorin calcium
Sensitive: A2 - Guideline
5-fluorouracil + leucovorin calcium
Sensitive
:
A2
RET fusion
Ampulla of Vater Carcinoma
RET fusion
Ampulla of Vater Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
NTRK3 fusion
Ampulla of Vater Carcinoma
NTRK3 fusion
Ampulla of Vater Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Ampulla of Vater Carcinoma
NTRK2 fusion
Ampulla of Vater Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Ampulla of Vater Carcinoma
NTRK1 fusion
Ampulla of Vater Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Ampulla of Vater Carcinoma
NTRK1 fusion
Ampulla of Vater Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Ampulla of Vater Carcinoma
NTRK2 fusion
Ampulla of Vater Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Ampulla of Vater Carcinoma
NTRK3 fusion
Ampulla of Vater Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Ampulla of Vater Carcinoma
No biomarker
Ampulla of Vater Carcinoma
durvalumab
Sensitive: A2 - Guideline
durvalumab
Sensitive
:
A2
durvalumab
Sensitive: A2 - Guideline
durvalumab
Sensitive
:
A2
No biomarker
Ampulla of Vater Carcinoma
No biomarker
Ampulla of Vater Carcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
KRAS G12C
Ampulla of Vater Carcinoma
KRAS G12C
Ampulla of Vater Carcinoma
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
MUC2 negative
Ampulla of Vater Carcinoma
MUC2 negative
Ampulla of Vater Carcinoma
gemcitabine
Resistant: C3 – Early Trials
gemcitabine
Resistant
:
C3
gemcitabine
Resistant: C3 – Early Trials
gemcitabine
Resistant
:
C3
KRT7 expression
Ampulla of Vater Carcinoma
KRT7 expression
Ampulla of Vater Carcinoma
gemcitabine
Resistant: C3 – Early Trials
gemcitabine
Resistant
:
C3
gemcitabine
Resistant: C3 – Early Trials
gemcitabine
Resistant
:
C3
KRT7 expression
Ampulla of Vater Carcinoma
KRT7 expression
Ampulla of Vater Carcinoma
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
C3
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
C3
KRT7 expression + MUC1 expression
Ampulla of Vater Carcinoma
KRT7 expression + MUC1 expression
Ampulla of Vater Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
C3
gemcitabine + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
C3
HER-2 mutation + CDK6 mutation
Ampulla of Vater Carcinoma
HER-2 mutation + CDK6 mutation
Ampulla of Vater Carcinoma
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk
Sensitive: C3 – Early Trials
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk
Sensitive
:
C3
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk
Sensitive: C3 – Early Trials
palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk
Sensitive
:
C3
BRAF D594G
Ampulla of Vater Carcinoma
BRAF D594G
Ampulla of Vater Carcinoma
binimetinib + encorafenib
Sensitive: C3 – Early Trials
binimetinib + encorafenib
Sensitive
:
C3
binimetinib + encorafenib
Sensitive: C3 – Early Trials
binimetinib + encorafenib
Sensitive
:
C3
MDM2 amplification
Ampulla of Vater Carcinoma
MDM2 amplification
Ampulla of Vater Carcinoma
BI 907828
Sensitive: C3 – Early Trials
BI 907828
Sensitive
:
C3
BI 907828
Sensitive: C3 – Early Trials
BI 907828
Sensitive
:
C3
PIK3CA mutation
Ampulla of Vater Carcinoma
PIK3CA mutation
Ampulla of Vater Carcinoma
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
NRAS mutation + BRAF mutation
Ampulla of Vater Carcinoma
NRAS mutation + BRAF mutation
Ampulla of Vater Carcinoma
MEK inhibitor
Sensitive: C4 – Case Studies
MEK inhibitor
Sensitive
:
C4
MEK inhibitor
Sensitive: C4 – Case Studies
MEK inhibitor
Sensitive
:
C4
HER-2 G660D + HER-2 S310F
Ampulla of Vater Carcinoma
HER-2 G660D + HER-2 S310F
Ampulla of Vater Carcinoma
afatinib
Sensitive: C4 – Case Studies
afatinib
Sensitive
:
C4
afatinib
Sensitive: C4 – Case Studies
afatinib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login